TTNP TITAN PHARMACEUTICALS INC Delisting Actions 8-K Filing 2024 - Nasdaq Compliance Issues Titan Pharmaceuticals received notices from Nasdaq for not filing its Q3 10-Q report on time and for failing to meet audit committee requirements due to a recent management change; the company has until January 21, 2025, to submit a compliance plan. Additionally, its auditor WithumSmith+Brown resigned following the departure of the CEO, but there were no disagreements on financial matters during their tenure.Get access to all SEC 8-K filings of the TITAN PHARMACEUTICALS INC